CHRM3 and colorectal cancer: For instance, darifenacin blocks the muscarinic acetylcholine receptor 3 in colorectal cancer cells, leading to a decrease in the p38, Erk and Akt signaling pathways, as well as the disruption of MMP-1 mRNA expression.